Vaxcyte

Vaxcyte, Inc. manufactures pharmaceutical products. The Company develops novel vaccines for infectious diseases.

P/E

Net profit

P/B

Book value

P/FCF

FCF

Yield

Growth potential

Report period	2018	2019	2020	2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Report period	2018	2019	2020	2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Ticker	Name	Type	Nominal value	ISIN	Price
PCVX:US	Vaxcyte	Common share	-	US92243G1085	$89.64

Vaxcyte news

10.05.2022

Vaxcyte's GAAP loss for 3 months of 2022 was $38.986 million, up 83.7% from $21.22 million in the previous year.

Source:

01.03.2022

Vaxcyte's GAAP loss for 2021 was $100.077 million, up 12.2% from $89.217 million the previous year.

Source:

11.11.2021

Vaxcyte's GAAP loss for 9M 2021 was $71.514 million, up 4.4% from $68.48 million in the prior year.

Source:

12.08.2021

Vaxcyte's GAAP loss for 6M 2021 was $44.899 million, down 5.4% from $47.462 million in the previous year.

Source:

General information

Company name	Vaxcyte
Sector	Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address	353 HATCH DR FOSTER CITY CA 94404 650-837-0111
Mailing address	353 HATCH DR FOSTER CITY CA 94404
Website	www.vaxcyte.com
Information disclosure	www.sec.gov

Vaxcyte balance sheet